recurrent marginal zone lymphoma
Showing 1 - 25 of >10,000
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- (no location specified)
Jun 2, 2022
Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)
Recruiting
- Marginal Zone Lymphoma
- Obinutuzumab, lenalidomide
-
Tianjin, Tian, ChinaInstitute of Hematology & Blood Diseases Hospital
Apr 27, 2023
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,
Completed
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +8 more
- PI3K inhibitor BKM120
- +3 more
-
Atlanta, Georgia
- +1 more
Jun 27, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +17 more
- Nivolumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent DLBCL Trial in Rochester (procedure, biological,
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +9 more
- Cryosurgery
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 9, 2022
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +20 more
- panobinostat
- +6 more
-
Scottsdale, Arizona
- +1 more
May 6, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of
Active, not recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +22 more
- Ibrutinib
- +3 more
-
Scottsdale, Arizona
- +1 more
Aug 10, 2021
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Hematopoietic Cell Transplantation Recipient, Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma Trial in Columbus
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +11 more
- Carmustine
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 29, 2021
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)
Not yet recruiting
- Follicular Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Terminated
- Adult Grade III Lymphomatoid Granulomatosis
- +116 more
- brentuximab vedotin
- +2 more
-
Chicago, Illinois
- +2 more
Aug 30, 2021
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)
Not yet recruiting
- OR Regimen Refractory Marginal Zone Lymphoma
- obrutinib, rituximab
- (no location specified)
Nov 12, 2023
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma
Completed
- Adult Grade III Lymphomatoid Granulomatosis
- +88 more
- bortezomib
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Apr 14, 2021
Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)
Not yet recruiting
- Marginal Zone Lymphoma
- (no location specified)
Nov 6, 2023